ProMetic Life Sciences (PLI) Scheduled to Post Quarterly Earnings on Monday
ProMetic Life Sciences (TSE:PLI) will issue its quarterly earnings data after the market closes on Monday, April 1st.
TSE:PLI opened at C$0.31 on Wednesday. ProMetic Life Sciences has a 1-year low of C$0.25 and a 1-year high of C$1.36. The company has a debt-to-equity ratio of 238.62, a quick ratio of 0.99 and a current ratio of 1.52. The firm has a market capitalization of $222.62 million and a P/E ratio of -1.69.
PLI has been the topic of a number of analyst reports. TD Securities lowered shares of ProMetic Life Sciences from a “hold” rating to a “reduce” rating and lowered their price objective for the company from C$0.60 to C$0.30 in a research report on Thursday, December 20th. National Bank Financial upgraded shares of ProMetic Life Sciences from an “underperform” rating to a “sector perform” rating and set a C$0.45 price objective on the stock in a research report on Monday, January 28th.
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Featured Article: Quick Ratio
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.